Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23085465 | 0.85 | NAAA (0.38) | EPHX1SMN1; SMN2HSD17B10NAAAGAA | |
| SCHEMBL22986118 | 0.81 | EPHX1 (0.41) | EPHX1SMN1; SMN2HSD17B10NAAAGAA | |
| SCHEMBL22570790 | 0.77 | EPHX1 (0.43) | EPHX1SMN1; SMN2HSD17B10NAAAGAA | |
| SCHEMBL24177609 | 0.74 | SIGMAR1 (0.41) | EPHX1SMN1; SMN2NAAA | |
| SCHEMBL18056091 | 0.74 | ITGB3 (0.43) | — | |
| SCHEMBL13057638 | 0.73 | LMNA (0.44) | EPHX1 | |
| SCHEMBL23025459 | 0.72 | CES2 (0.39) | SMN1; SMN2HSD17B10GAACES2CES1 | |
| SCHEMBL14796570 | 0.72 | TP53 (0.35) | EPHX1GAAL3MBTL1 | |
| SCHEMBL14852789 | 0.72 | TP53 (0.35) | EPHX1GAAL3MBTL1 | |
| SCHEMBL8224071 | 0.71 | EPHX2 (0.42) | EPHX1NAAAGAACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210046160-A1 | Immuno Oncology Combination Therapies With IL-2 Conjugates | Synthorx, Inc. (US) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210046160-A1 | Immuno Oncology Combination Therapies With IL-2 Conjugates | IL2, IL2RA, IL15 | EPHX1 2753/4885SMN1; SMN2 1855/4885HSD17B10 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.